A Novel Analog Reasoning Paradigm: New Insights in Intellectually Disabled Patients.
Aurore Curie, Amandine Brun, Anne Cheylus...
https://pubmed.ncbi.nlm.nih.gov/26918704/Actively Recruiting
Led by Centre Hospitalier Universitaire Dijon · Updated on 2026-02-24
20
Participants Needed
13
Research Sites
N/A
Total Duration
Researchers are evaluating the efficacy and safety of alpelisib BYL719 in both children and adults diagnosed with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome MCAP, a neurodevelopmental disorder. This Phase II trial includes a 6-month double-blind, placebo-controlled period followed by an open-label treatment phase, aiming to provide a total of 24 months of treatment. The study focuses on assessing behavioral and neurological improvements and monitoring safety in participants aged 2 to 40 years. Participants will be randomly assigned to receive either alpelisib or a matching placebo once daily during the first 6 months. After this period, all participants enter an open-label phase where they receive alpelisib for up to 24 months. Dose adjustments may occur for children aged 5 and older depending on their response and tolerance. Optional lumbar punctures and blood samples will be collected between 6 and 24 months to analyze drug levels. Throughout the study, participants will be followed monthly at local centers with regular clinical, biological, neuropsychological, and functional assessments at baseline and every 6 months. Brain volumetric MRI scans will be performed at the start and after 24 months. The main outcome measured is the proportion of participants showing improvement on the Vineland II Adaptive Behavior Scale after 24 months. Safety and other neurological and quality of life measures will also be monitored. Participants may discontinue treatment early for toxicity, disease progression, or other reasons.
CONDITIONS
Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)
L
Laurence OLIVIER-FAIVRE
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Centre Hospitalier Universitaire Dijon
Lead Sponsor
Novartis Pharmaceuticals
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 90 days
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Duration - 6 months for double-blind period followed by up to 18 months open label period, totaling 24 months
Participants receive either alpelisib or placebo daily for the first 6 months. After 6 months, all participants receive alpelisib in an open label period up to 24 months total treatment duration.
Monthly visits in local centres and assessments every 6 months
Duration - 24 months concurrent with treatment duration
Participants are monitored with clinical, biological, neuropsychological, and functional evaluations at baseline, every 6 months, and volumetric MRI at baseline and 24 months.
Assessments at baseline, 6, 12, 18, and 24 months; MRI at baseline and 24 months
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Aurore Curie, Amandine Brun, Anne Cheylus...
https://pubmed.ncbi.nlm.nih.gov/26918704/Maxime Luu, Pierre Vabres, Aurélie Espitalier...
https://pubmed.ncbi.nlm.nih.gov/39806603/Centre Hospitalier Universitaire Dijon
Lead Sponsor
Novartis Pharmaceuticals
Collaborating Sponsor